| Digg It |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Workplace Communication > How to Communicate After the Merger/Downsize |
|
Digg It - How to Communicate After the Merger/Downsize
Workplace communication allows organizations to promote and coordinate personal or group action, foster positive interperson According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product al relationships and cultivate an atmosphere that is comfortable for today’s diverse workforce. Most mergers and acquisitio ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ns, or downsize begin in the planning stages are about dollars, cents and legal issues; but after the lawyers and accountant lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. s complete the deal, it becomes very clear that mergers are about people. Communication is the life-blood of productive work here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe place and good relationships with customers’ mergers and acquisitions wreak havoc on the normal flow of communication within d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro a company. Usually, in the early stages of a downsize or merger, everyone knows change is coming, but the direction is not ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc always clear. Employees suspect management knows a lot more than they are telling, especially if a downsize springs up wit easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi hout warning. Employees become very suspicious and wonder if they will be downsized and when it might happen. At this stag nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically e, employees feel threatened by change and stop sharing information because they do not know whom to trust. At the same tim and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ e, internal communication is ceased, just when it is needed most. This happens for a specific reason. Management in the or ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ganization must be discreet about the information they share; they may not know how many employees they will have to let go, ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a or what division will no longer exist. When downsize occur, managers are often governed by lawyers and dictated by account dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod ants or “number-crunchers.” The “number-crunchers” are not involved in dealing with people or how to communicate with peopl cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin e; they are merely interested in finding ways to cut back within the organization since they are not involved with dealing w tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen ith people, their choice of cut back is “people.” If you have been downsized, loosing you job hurts! This is a variety of l t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel ife-altering events, such as death in the family, divorce, and serious illness. Loosing your job ranks among the highest in ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust stress-causing situations. Job loss can have a profound effect on your emotional well-being. There is a typical cycle tha y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products t most people experience. This cycle includes denial, anger, frustration, and eventually severe depression. If you find yo . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de urself experiencing this, get help dealing with the emotional effects and the life changing effects. Clear and consistent c elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip ommunication enhances your personal communication; it is the fundamental building block of everything any human being can do tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Hiding Behind Numbers in Modern Corporations How Much Do You Pay Your Employer To Work For Them?
|